[Research Report] The gastrointestinal drugs market size is expected to grow from US$ 49,043.38 million in 2019 to US$ 71,300.28 million by 2027; it is estimated to record a CAGR of 4.9% from 2020 to 2027.

Analyst Perspective

Rising investments in the development of biologics and the emergence of a biosimilar are expected to grow at a lucrative rate over the forecast period. Pharmaceutical companies are investing in research and development to discover new and improved gastrointestinal drugs. These are improved gastrointestinal drugs and these advancements have led to the introduction of innovative medications with enhanced efficacy, improved tolerability, and fewer side effects. Newer drugs options provide healthcare providers with more treatment choices and better outcomes for patients. There has been an improvement in medical awareness and diagnostic techniques for gastrointestinal disorder. This has led to earlier and more accurate diagnosis, prompting healthcare providers to prescribe appropriate medications for treatment. With increased awareness among patients, there is also a higher demand for effective drugs to alleviate symptoms and improve quality of life. Additionally, the presence of highly advanced medical care facilities and high healthcare expenditure are boosting the gastrointestinal drugs market growth in various regions.

Market Overview

Gastrointestinal drugs are a category of medications that are used to treat disorders and conditions related to the gastrointestinal system, which includes the organs involved in digestion, absorption, and elimination of food and waste. Various factors can contribute to GI disorder, including infections, inflammation, acid secretion imbalances, ulcers, and other structural abnormalities. Some gastrointestinal disorders involve abnormal mobility, which affects the movement of food through the digestive tract. Drugs that enhance or regulate motility, such as prokinetic agents, can be used to treat conditions like gastroparesis or irritable bowel syndrome (IBS). Also, growing incidences of chronic constipation among all age groups, increasing over-the-counter sales, increasing demand for laxatives, and increasing product offerings from manufacturers contributes to the growth of the gastrointestinal drugs market.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Gastrointestinal Drugs Market: Strategic Insights

Gastrointestinal Drugs Market

• 
  CAGR (2019 - 2027)

  5.4%
• Market Size 2019
  US$ 49.04 Billion
• Market Size 2027
  US$ 71.3 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Sanofi
• GlaxoSmithKline plc
• Johnson and Johnson Services, Inc.
• Bausch Health
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Bayer AG
• Celltrion Healthcare Co.,Ltd

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Drug Class

• Acid Neutralizers
• Antidiarrheal and Laxatives
• Anti-Inflammatory Drugs
• Antiemetic and Antinauseants
• Biologics
• Others

Route of Administration

• Oral
• Parenteral

Application

• Inflammatory Ulcerative Colitis
• Crohn's Disease
• Irritable Bowel Syndrome
• Gastroenteritis
• Celiac Disease
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

 

Market Driver

Increase in Development of Biologics to Drive Global Gastrointestinal Drugs Market Growth

Increasing development of biologics for the treatment of GI diseases is driving the growth of the market. In the last few years, new treatments called biologics are being used for the treatment of inflammatory diseases.  Currently, the FDA has approved Humira, Cimzia, Remicade, Simponi, Tysabri, and Entyvio biologics for the treatment of Crohn’s disease and ulcerative colitis. Biologics have revolutionized the IBD treatment, and their success in the treatment of these indications is driving the use of biologics in other GI conditions, such as celiac disease, eosinophilic esophagitis, and autoimmune hepatitis. The development of new medication is driving the growth of the market. For instance, in September 2019, Janssen Pharmaceutical received the European Commission approval for STELARA. It will be used in the treatment of moderately to severely active ulcerative colitis in adults. It is the first biologic treatment that will target the IL-12/IL-23 pathway, an important therapeutic target in UC. Apart from this, strategic initiatives by market players, such as product launch in untapped markets, are further driving the growth of the market. For instance, in July 2020, Takeda Pharmaceutical Company launched its blockbuster biologic drug Vedolizumab in India as part of its GI portfolio. Vedolizumab would be sold in India under the brand name Kynteles. It would be used for the treatment of chronic inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease.  The cases of GI disorders are on the rise in developing countries. For instance, there are currently around 1.5 million IBD patients in India. The introduction of new biologics in these markets is expected to drive the market growth during the forecast period.

Moreover, along with product launches, the market players are carrying out different strategies to add innovative therapies in their product portfolio. This is further driving the growth of the gastrointestinal drugs market. For instance, in February 2020, Takeda Pharmaceutical Company Limited acquired PvP Biologics, Inc. This acquisition added investigational medicine TAK-062 (Kuma062) in the company's GI portfolio, which would be used for the treatment of uncontrolled celiac disease. The company is planning to submit data from the Phase 1 study for presentation at an upcoming medical congress. Globally, many people are living with celiac disease, and they manage their symptoms by following a gluten-free diet.  There is still no treatment for people who experience severe symptoms. With this acquisition, the company is expecting to bring new therapies in the area of celiac disease management

Segmental Analysis

Based on application, the gastrointestinal drugs market is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. In 2019, the inflammatory ulcerative colitis segment held a larger share of the gastrointestinal drugs market. However, the irritable bowel syndrome segment is anticipated to register the highest CAGR in the gastrointestinal drugs market during the forecast period. The growing prevalence of Ulcerative colitis (UC) is driving the adoption of GI drugs in the forecast period for the gastrointestinal drugs market. As per the study published in NCBI, In the US, 34 children per 100,000 persons have UC, while for adults the prevalence is 263 per 100,000 persons. Also, the growth of this segment can be attributed to easy availability of drugs to treat this condition. In addition, many manufactures have launched a wide range of biologics for UC, which is further driving the growth of the gastrointestinal drugs market. For instance, Takeda Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer are among the top companies that have established themselves in the market with their products for the treatment of inflammatory ulcerative colitis. 

Regional Analysis

The Asia- Pacific gastrointestinal drugs market was valued at US$ 8,868.44 million in 2019 and is projected to reach US$ 13,618.35 million by 2027; it is expected to grow at a CAGR of 5.6% during the forecast period. The Asia-Pacific gastrointestinal drugs market is segmented into the China, Japan, India, Australia, South Korea and Rest of Asia Pacific. The Japan held the largest share of the Asia-Pacific gastrointestinal drugs market in 2019. The growth of the gastrointestinal drugs market in the country is primarily driven by growing prevalence of gastrointestinal diseases in Japan which is likely to demand gastrointestinal drugs. As per the study ‘Trends in Gastrointestinal Diseases in Japan’, the incidence of gastric cancer is high in East Asian countries, including Japan. It also reported that incidence of gastroesophageal reflux disease (GERD) and IBD is continuously increasing, which will fuel the growth of gastrointestinal drugs market.

Moreover, new product launches and funding for research purposes also drive the gastrointestinal drugs market growth in the US. For instance, In June 2023, Astellas Pharma Inc. announced the submission of a New Drug Application to Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. Thus, above mentioned factors are expected to propel the gastrointestinal drugs market growth in the Asia-Pacific region.

Key Player Analysis

The gastrointestinal drugs market analysis consists of players, such as Sanofi, GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Bausch Health, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Celltrion Healthcare Co.,Ltd., and LEXICON PHARMACEUTICALS, INC, among others are the top two players owing to the diversified product portfolio offered.

Gastrointestinal Drugs Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

 

Recent Developments

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the gastrointestinal drugs market. A few recent key market developments in the gastrointestinal drugs market are listed below: 

• In July 2020, Celltrion Healthcare received marketing authorization approval the European Commission (EC) for Remsima (infliximab, CT-P13). It is a subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis.
• In May 2020, Sanofi a leading manufacturer of brands such as Buscopan for irritable Bowel Syndrome and Dulcolax for constipation relief has entered into the digestive wellbeing market space with the launch of a new food supplement, Buscobiota. Buscobiota comprised of three types of Lactobacillus and two types of Bifidobacterium which can be used as a preventive medication for chronic constipation.